EU OKs Difelikefalin for CKD-Associated Pruritus, Generic Diabetes Meds

CHMP adopts positive opinions for a new drug for pruritis associated with chronic kidney disease, two biosimilar insulins, and a generic form of the DPP-4 inhibitor sitagliptin for type 2 diabetes.
International Approvals
CHMP adopts positive opinions for a new drug for pruritis associated with chronic kidney disease, two biosimilar insulins, and a generic form of the DPP-4 inhibitor sitagliptin for type 2 diabetes.
International Approvals